Portal de Periódicos da CAPES

VASOACTIVE COCKTAILS FOR ERECTILE DYSFUNCTION: CHEMICAL STABILITY OF PGE1, PARAVERINE AND PHENTOLAMINE

1998; Lippincott Williams & Wilkins; Volume: 160; Issue: 2 Linguagem: Inglês

10.1016/s0022-5347(01)62957-4

1527-3792

Marcello Soli, Alessandro Bertaccini, F. Carparelli, Roberto Gotti, Vanni Cavrini, Vincenza Andrisano, Giuseppe Martorana,

Sexual Differentiation and Disorders

No AccessJournal of UrologyInvestigative Urology1 Aug 1998VASOACTIVE COCKTAILS FOR ERECTILE DYSFUNCTION: CHEMICAL STABILITY OF PGE1, PARAVERINE AND PHENTOLAMINE MARCELLO SOLI, ALESSANDRO BERTACCINI, FRANCESCO CARPARELLI, ROBERTO GOTTI, VANNI CAVRINI, VINCENZA ANDRISANO, and GIUSEPPE MARTORANA MARCELLO SOLIMARCELLO SOLI , ALESSANDRO BERTACCINIALESSANDRO BERTACCINI , FRANCESCO CARPARELLIFRANCESCO CARPARELLI , ROBERTO GOTTIROBERTO GOTTI , VANNI CAVRINIVANNI CAVRINI , VINCENZA ANDRISANOVINCENZA ANDRISANO , and GIUSEPPE MARTORANAGIUSEPPE MARTORANA View All Author Informationhttps://doi.org/10.1016/S0022-5347(01)62957-4AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: Vasoactive cocktails are widely used in diagnosing and treating erectile dysfunction, especially in poor responders to prostaglandin E1 (PGE1). However, very little information as to their chemical interactions and stability is available, despite the huge amount of published work regarding their clinical efficacy. Obviously, medical and legal problems are involved. Materials and Methods: We analyzed four kinds of vasoactive cocktails, composed of papaverine, phentolamine and PGE1 in different combinations, using High Performance Liquid Chromatography analysis after 5 to 60 days of storage at temperatures between 2 and 8C. SPSS MANOVA analysis and a t-test for paired samples were used for statistical purposes. Results: Papaverine and phentolamine concentrations showed no significant variations during the 2 month study, ranging from a minimum of 96.75 +/− 1.20 to a maximum of 103.00 +/− 0.20% of the starting values. In the same period, PGE1 showed an accelerated degradation profile, reaching concentration values, after 60 days, of 76.00 +/− 2.28% and 70.20 +/− 2.02% when added to phentolamine or papaverine respectively and 70.00 +/− 2.40% with both. Conclusions: Papaverine and phentolamine are characterized by chemical stability when blended together or with PGE1. Papaverine and/or phentolamine increase the naturally occurring degradation of PGE1 in physiological solution. This effect is most evident in the first 10 days. Papaverine has the greatest deteriorating effect on PGE1. A safe and proper use of these cocktails should take into account the variations of PGE1 concentration. References 1 : 15 Years of injection therapy in erectile dysfunction - a review. Int. J. Imp. Res.1996; 8: 114. Google Scholar 2 : Prostaglandin E1 versus phentolamine/papaverine for the treatment of erectile impotence: a double-blind comparison. J. Urol.1989; 141: 549. Link, Google Scholar 3 : Rescuing the failed papaverine-phentolamine erection: a proposed synergistic action of papaverine phentolamine, and PGE1. J. Urol.1990; 143: 304A. Google Scholar 4 : Selectivity and Detectability Optimization in HPLC. New York: John Wiley & Sons1989. Google Scholar 5 : Using Multivariate Statistics. : Harper Collins, College Publishers1996: 375. Google Scholar 6 : A comparison of the response to the intracavernosal injection of a combination of papaverine and phentolamine, prostaglandin PGE1 and a combination of all three agents in the management of impotence. Int. J. Impotence Res.1991; 3: 113. Google Scholar 7 : Comparison of effects following the intracorporeal injection of papaverine and prostaglandin E1. Br J. Urol.1992; 69: 404. Google Scholar 8 : Stability study of prostaglandin E1 (PGE1) in physiological solutions by liquid chromatography (HPLC). Int. J. Pharm.1995; 115: 103. Google Scholar 9 : First comparison of alprostadil sterile powder (Caverject) with tri-mix nomogram and patient satisfaction. Int. J. Imp. Res.1996; 8: 113. Google Scholar 10 : Alprostadil sterile powder formulation for intracavernous treatment of erectile dysfunction. Eur. Urol.1996; 29. Google Scholar 11 : Combination intracavernous pharmacotherapy in the management of male erectile dysfunction. Int. J. Impotence Res.1992; 4: 109. Google Scholar 12 : Four-drugs intracavernous therapy for impotence due to corporal veno-occlusive dysfunction. J. Urol.1993; 149: 1291. Abstract, Google Scholar 13 : Papaverine-phentolamine and prostaglandin E1 versus papaverine-phentolamine alone for intracorporeal injection therapy: a clinical double-blind study. J. Urol.1995; 154. Google Scholar 14 : Erectile responses to intracavernous papaverine and phentolamine: comparison of single and combined delivery. J. Urol.1988; 140: 1415. Link, Google Scholar 15 : Intravenous self-injection of vasoactive drugs in the treatment of impotence: 8 years experience with 615 cases. J. Urol.1991; 145: 287. Abstract, Google Scholar 16 : Penile response to intracavernosal vasoactive intestinal polypeptide alone and in combination with other vasoactive agents. Br. J. Urol.1989; 64: 191. Google Scholar 17 : A pilot study of the role of intracavernous injection of vasoactive intestinal peptide (VIP) and phentolamine mesylate in the treatment of erectile dysfunction. Int. J. Imp. Res.1996; 8: 115. Google Scholar 18 : Prostaglandin E, and the nitric oxide donor linsidomine for erectile failure: a diagnostic comparative study of 40 patients. J. Urol.1993; 149: 1280. Abstract, Google Scholar 19 : Penile erection induced by vasoactive intestinal peptide and sodium nitroprusside. Urol. Res.1993; 21: 75. Google Scholar 20 : Forskolin: a promising new adjunct to intracavernous pharmacotherapy. J. Urol.1996; 155: 1789. Link, Google Scholar 21 : Follow up results of a combination of calcitonin gene related peptide and prostaglandin E1 in the treatment of erectile dysfunction. J. Urol.1993; 149: 1296. Abstract, Google Scholar 22 : The pH analysis of papaverine - phentolamine and prostaglandin E1 for pharmacologic erection. J. Urol.1989; 141: 1458. Abstract, Google Scholar Departments of Urology and Pharmaceutic Science, University of Bologna, Bologna, Italy© 1998 by American Urological Association, Inc.FiguresReferencesRelatedDetails Volume 160Issue 2August 1998Page: 551-555 Advertisement Copyright & Permissions© 1998 by American Urological Association, Inc.MetricsAuthor Information MARCELLO SOLI (SOLI) Requests for reprints: Department of Urology, University of Bologna, via Massarenti 9, 40139 Bologna, Italy. More articles by this author ALESSANDRO BERTACCINI More articles by this author FRANCESCO CARPARELLI More articles by this author ROBERTO GOTTI More articles by this author VANNI CAVRINI More articles by this author VINCENZA ANDRISANO More articles by this author GIUSEPPE MARTORANA More articles by this author Expand All Advertisement PDF downloadLoading ...